Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review

Asia-Pacific Journal of Clinical Oncology

Volumn 13, Issue 6, 2017, Pages 345-355

  Pulvers, Jeremy N ^a   Marx, Gavin ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SYDNEY ADVENTIST HOSPITAL   (Australia)

Author keywords

colorectal cancer; FOLFOX; neuropathy; neurotoxicity; oxaliplatin

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

AGE; ALCOHOL CONSUMPTION; ANEMIA; BODY SURFACE; CANCER STAGING; COLORECTAL CANCER; COMORBIDITY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; ENVIRONMENTAL TEMPERATURE; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK; RISK FACTOR; SEASONAL VARIATION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; FEMALE; MALE; MIDDLE AGED; PROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES;

EID: 85021310638     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12694     Document Type: Review

References (74)

1. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist. 2004;9:8–12.
2. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 1990;25:299–303.
3. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351.
4. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30.
5. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
6. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–3516.
7. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997;33:214–219.
8. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947.
9. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084–2091.
10. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–2019.
11. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249:9–17.
12. Misset JL. Oxaliplatin in practice. Br J Cancer. 1998;77(Suppl 4):4–7.
13. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol. 1998;25:13–22.
14. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother. 2005;39:128–135.
15. Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag. 2005;1:249–258.
16. Zedan AH, Hansen TF, Fex Svenningsen A, Vilholm OJ. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers. Clin Colorectal Cancer. 2014;13:73–80.
17. Pachman DR, Qin R, Seisler DK, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol. 2015;33:3416–3422.
18. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002;20:1767–1774.
19. Beijers AJ, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. 2014;22:1999–2007.
20. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002;29:21–33.
21. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005;5(Suppl 1):S38–S46.
22. Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006;59:159–168.
23. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008;34: 368–377.
24. Tofthagen C. Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med. 2010;13:1389–1391.
25. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist. 2011;16:708–716.
26. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013;31:2699–2707.
27. Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer. 2013;21:3307–3313.
28. Jordan B, Jahn F, Beckmann J, Unverzagt S, Muller-Tidow C, Jordan K. Calcium and magnesium infusions for the prevention of oxaliplatin-induced peripheral neurotoxicity: a systematic review. Oncology. 2016;90:299–306.
29. Vincenzi B, Frezza AM, Schiavon G, et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.[Erratum appears in Support Care Cancer. 2013 Apr;21(4):1209 Note: Silvestris, Nicola [added]]. Support Care Cancer. 2013;21:1313–1319.
30. Velasco R, Bruna J, Briani C, et al. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry. 2014;85:392–398.
31. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009;8:10–16.
32. Won HH, Lee J, Park JO, et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012;118:2828–2836.
33. Ali BH. Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature. Basic Clin Pharmacol Toxicol. 2010;106:272–279.
34. Di Francia R, Siesto RS, Valente D, et al. Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. Anticancer Drugs. 2013;24:1069–1078.
35. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology. 2003;61:1297–1300.
36. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007;12:210–225.
37. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33:15–49.
38. Baek KK, Lee J, Park SH, et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat. 2010;42:185–190.
39. Cleeland CS, Farrar JT, Hausheer FH. Assessment of cancer-related neuropathy and neuropathic pain. Oncologist. 2010;15(Suppl 2):13–18.
40. Oldenburg J, Fossa SD. Exploration of platinum-induced neuropathy should be based on both objective and subjective examinations. Acta Oncol. 2009;48:804-6.
41. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-8.
42. R Core Team (2015) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/
43. Lumley T (2012) rmeta: Meta-analysis. R package version 2.16. http://CRAN.R-project.org/package=rmeta
44. Shen QP, Fan MZ, Lai L. Analysis of correlative factors of neurotoxicity of gastric cancer and intestinal cancer patients after radical resection with oxaliplatin chemotherapy. [Chinese]. J Prac Oncol. 2011;26:266–268.
45. Liu H, Wang L, Jia J, Liu Y, Wang F, Li H. Clinical observation and follow-up study on oxaliplatin-related neurotoxicity in patients with resectable colorectal cancer. [Chinese]. J Clin Oncol. 2013;40:725–729.
46. Satomi M, Kono T, Mamiya N, et al. [Survey of oxaliplatin-associated peripheral sensory neuropathy using an interview-based questionnaire in patients with advanced colorectal cancer]. Gan To Kagaku Ryoho. 2009;36:1321–1325.
47. Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119:438–444.
48. Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009;144:245–252.
49. Altaf R, Lund Brixen A, Kristensen B, Nielsen SE. Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. Oncology. 2014;87:167–172.
50. Brouwers EE, Huitema AD, Boogerd W, Beijnen JH, Schellens JH. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol. 2009;48:832–841.
51. Hossain S, Rahman S, Zahid A. Chlorine level as a predictive factor for oxaliplatin-induced peripheral neuropathy. J Med Sci. 2011;11:185–191.
52. Kanbayashi Y, Hosokawa T, Okamoto K, et al. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs. 2010;21:877–881.
53. Ramanathan RK, Rothenberg ML, de Gramont A, et al. Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol. 2010;21:754–758.
54. Sugihara K, Ohtsu A, Shimada Y, et al. Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Cancer Med. 2012;1:198–206.
55. Uwah AN, Ackler J, Leighton JC, Jr., Pomerantz S, Tester W. The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer. 2012;11:275–279.
56. Wiela-Hojenska A, Kowalska T, Filipczyk-Cisarz E, Lapinski L, Nartowski K. Evaluation of the toxicity of anticancer chemotherapy in patients with colon cancer. Adv. 2015;24:103–111.
57. Alejandro LM, Behrendt CE, Chen K, Openshaw H, Shibata S. Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol. 2013;36:331–337.
58. Vatandoust S, Joshi R, Pittman KB, et al. A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Support Care Cancer. 2014;22:513–518.
59. Lee P-H, Park Y-S, Ji J-F, Fu Y-T, Ratanatharathorn V. Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: The MASCOT study. Asia Pac J Clin Oncol. 2009;5:101–110.
60. Argyriou AA, Briani C, Cavaletti G, et al. Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study. Eur J Neurol. 2013;20:788–794.
61. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6:1205–1218.
62. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993;53:5970–5976.
63. Peng J, Mandal R, Sawyer M, Li XF. Characterization of intact hemoglobin and oxaliplatin interaction by nanoelectrospray ionization tandem mass spectrometry. Clin Chem. 2005;51:2274–2281.
64. Lemma T, Pawliszyn J. Human serum albumin interaction with oxaliplatin studied by capillary isoelectric focusing with the whole column imaging detection and spectroscopic method. J Pharm Biomed Anal. 2009;50:570–575.
65. Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs. 2000;60:895–924.
66. Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res. 2004;21:891–894.
67. Luo FR, Wyrick SD, Chaney SG. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res. 1998;10:595–603.
68. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10:4055–4061.
69. Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014;32:997–1005.
70. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11–21.
71. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–890.
72. Kellogg AP, Cheng HT, Pop-Busui R. Cyclooxygenase-2 pathway as a potential therapeutic target in diabetic peripheral neuropathy. Curr Drug Targets. 2008;9:68–76.
73. Kellogg AP, Wiggin TD, Larkin DD, Hayes JM, Stevens MJ, Pop-Busui R. Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes. Diabetes. 2007;56:2997–3005.
74. Ma W, Quirion R. Does COX2-dependent PGE2 play a role in neuropathic pain? Neurosci Lett. 2008;437:165–169.